

1           **Serum-IgG responses to SARS-CoV-2 after mild and severe**  
2           **COVID-19 infection and analysis of IgG non-responders**

3  
4   Emelie Marklund, MD<sup>1,2</sup>, Susannah Leach, MD PhD<sup>3,4</sup>, Hannes Axelsson, MSc<sup>3</sup>, Kristina  
5   Nyström, PhD<sup>1</sup>, Heléne Norder, MD PhD<sup>1,5</sup>, Mats Bemark, PhD<sup>3,6</sup>, Davide Angeletti, PhD<sup>3</sup>,  
6   Anna Lundgren, PhD<sup>3,5</sup>, Staffan Nilsson, PhD<sup>7,8</sup>, Lars-Magnus Andersson, MD PhD<sup>1,2</sup>, Aylin  
7   Yilmaz, MD PhD<sup>1,2</sup>, Magnus Lindh, MD PhD<sup>1,5</sup>, Jan-Åke Liljeqvist, MD PhD<sup>1,5</sup>, Magnus  
8   Gisslén, MD PhD<sup>1,2\*</sup>

9   <sup>1</sup>Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg,  
10   Gothenburg, Sweden. <sup>2</sup>Department of Infectious Diseases, Sahlgrenska University Hospital,  
11   Gothenburg, Sweden. <sup>3</sup>Department of Microbiology and Immunology, Sahlgrenska Academy,  
12   University of Gothenburg, Gothenburg, Sweden. <sup>4</sup>Department of Clinical Pharmacology,  
13   Sahlgrenska University Hospital, Gothenburg, Sweden. <sup>5</sup>Department of Clinical  
14   Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden. <sup>6</sup>Department of  
15   Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital,  
16   Gothenburg, Sweden. <sup>7</sup>Department of Mathematical Sciences, Chalmers University of  
17   Technology, Gothenburg, Sweden. <sup>8</sup>Department of Laboratory Medicine, Sahlgrenska  
18   Academy, University of Gothenburg, Gothenburg, Sweden.

19  
20   \*Corresponding author:

21   Magnus Gisslén, Dept. of Infectious Diseases, Sahlgrenska University Hospital, 416 50  
22   Gothenburg, Sweden. Phone: +46 31 3435519, e-mail: [magnus.gisslen@gu.se](mailto:magnus.gisslen@gu.se)

23  
24

## 25 **Abstract**

26 *Background:* To accurately interpret COVID-19 seroprevalence surveys, knowledge of  
27 serum-IgG responses to SARS-CoV-2 with a better understanding of patients who do not  
28 seroconvert, is imperative. This study aimed to describe serum-IgG responses to SARS-CoV-  
29 2 in a cohort of patients with both severe and mild COVID-19, including extended studies of  
30 patients who remained seronegative more than 90 days post symptom onset.

31 *Results:* Forty-seven patients (mean age 49 years, 38% female) were included. All (15/15)  
32 patients with severe symptoms and 29/32 (90.6%) patients with mild symptoms of COVID-19  
33 developed SARS-CoV-2-specific IgG antibodies in serum. Time to seroconversion was  
34 significantly shorter (median 11 vs. 22 days,  $P=0.04$ ) in patients with severe compared to  
35 mild symptoms. Of the three patients without detectable IgG-responses after >90 days, all had  
36 detectable virus-neutralizing antibodies and in two, spike-protein receptor binding domain-  
37 specific IgG was detected with an in-house assay. Antibody titers were preserved during  
38 follow-up and all patients who seroconverted, irrespective of the severity of symptoms, still  
39 had detectable IgG levels >75 days post symptom onset.

40 *Conclusions:* Patients with severe COVID-19 both seroconvert earlier and develop higher  
41 concentrations of SARS-CoV-2-specific IgG than patients with mild symptoms. Of those  
42 patients who not develop detectable IgG antibodies, all have detectable virus-neutralizing  
43 antibodies, suggesting immunity. Our results showing that not all COVID-19 patients develop  
44 detectable IgG using two validated commercial clinical methods, even over time, are vital for  
45 the interpretation of COVID-19 seroprevalence surveys and for estimating the true infection  
46 prevalence in populations.

47 *Keywords*

48 SARS-CoV-2, COVID-19, IgG, neutralizing antibodies, disease severity

49

## 50 **Introduction**

51 The coronavirus disease 2019 (COVID-19) pandemic continues, causing considerable  
52 morbidity and mortality worldwide. The severity of COVID-19 ranges from asymptomatic to  
53 fatal pneumonitis, with mildly symptomatic patients accounting for approximately 80% of all  
54 cases according to current understanding (1). Severe acute respiratory syndrome coronavirus  
55 2 (SARS-CoV-2), the causative agent of COVID-19, gains entry to human cells by binding  
56 the angiotensin-converting enzyme 2 (ACE2) receptor with the receptor-binding domain  
57 (RBD) of its spike (S) protein (2). Thus, antibodies targeting the S-protein may effectively  
58 neutralize the virus (3). Seroprevalence studies usually measure SARS-CoV-2 S- and  
59 nucleocapsid (N-) protein specific IgG antibodies; whether these antibodies correlate with  
60 protective immunity is however still unknown.

61 The serological responses to other beta-coronaviruses vary. Whilst all patients infected  
62 by SARS-CoV were found to develop IgG antibodies (4), some patients with mild symptoms  
63 of MERS-CoV failed to develop detectable levels of IgG (5). Several short follow-up studies  
64 of mostly hospitalized patients have reported the development of IgG in serum against SARS-  
65 CoV-2 in the majority of patients (3,6–10). When patients remain seronegative, it is often  
66 concluded that seroconversion would likely occur later; serological findings over a longer  
67 period than 30 days post symptom onset (PSO) remain limited. Further investigation of  
68 patients who fail to produce detectable levels of IgG is lacking and antibody responses in  
69 patients with mild symptoms are also poorly described. Here, we investigated serum-IgG (S-  
70 IgG) responses to SARS-CoV-2 in a cohort of patients with both severe and mild COVID-19,  
71 profiling the patients who remained seronegative.

72

73

## 74 **Materials and Methods**

### 75 **Patients and sample collection**

76 A cohort of 47 patients were recruited between February 25<sup>th</sup> and March 25<sup>th</sup> 2020, at the  
77 Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.  
78 The study protocol was approved by the Swedish Ethical Review Authority (Registration  
79 number 2020-01771) and patients were included after written informed consent. Disease  
80 severity was divided into severe and mild: severe cases were defined as those requiring  
81 invasive mechanical ventilation or high-flow nasal oxygen, and mild cases as not requiring  
82 oxygen nor in-patient hospital care (11). Blood samples were collected during hospitalization  
83 and/or during follow-ups. Seroconversion was defined as detectable levels of SARS-CoV-2-  
84 specific IgG antibodies in serum.

### 85 **Real-time polymerase chain reaction (RT-PCR) assay**

86 All patients had been diagnosed with SARS-CoV-2 with RT-PCR from the upper respiratory  
87 tract (pooled nasopharyngeal and throat swabs) during acute phase of the infection. Nucleic  
88 acid was extracted from clinical samples in a MagNA Pure 96 instrument using the Total  
89 Nucleic Acid isolation kit (Roche). RT-PCR targeting the RdRP region was performed in a  
90 QuantStudio 6 instrument (Applied Biosystems, Foster City, CA) using the primers and probe  
91 described (12). Cycle threshold (Ct) values <38 were regarded as positive.

### 92 **Detection of SARS-CoV-2 specific serum antibodies**

93 Serum-IgG antibodies against SARS-CoV-2 were analyzed using two commercially available  
94 serological assays: the qualitative Architect chemiluminescent microparticle immunoassay  
95 (Abbott Laboratories, USA), measuring IgG against SARS-CoV-2 N-protein, and the  
96 quantitative iFlash 1800 chemiluminescent immunoassay (YHLO, China), which measures  
97 IgG against both SARS-CoV-2 S- and N-proteins. All samples were analyzed using both

98 assays. IgG concentrations were obtained using the iFlash 1800 assay, and  $\geq 10$  AU/ml were  
99 defined as positive. The time of seroconversion was defined as the time-point at which the  
100 first positive serum-IgG result was observed.

101 RBD ELISA was performed as previously described (13) with some modification.  
102 Briefly, plates were coated with 4 $\mu$ g/mL SARS-CoV2 RBD locally produced in 293F cells in  
103 PBS and incubated overnight at 4°C. Blocking was done with 2% sterile filtered BSA in PBS  
104 at RT. Plates were washed with PBS + 0.05% Tween and incubated with twofold serially  
105 diluted sera, starting at 1:50. After washing, plates were incubated with secondary antibodies  
106 diluted in PBS + 0.05% Tween: Goat Anti-Human IgG Fc-HRP (Southern Biotech  
107 Associates, Birmingham, AL; 2048-05), Goat Anti-Human IgA-HRP (SouthernBiotech,  
108 2050-05), Goat Anti-Human IgM-HRP (SouthernBiotech, 2020-05), all diluted 1:6000. Plates  
109 were developed with 1-step Ultra TMB-ELISA (ThermoFisher, 34029), reaction stopped by  
110 2M H<sub>2</sub>SO<sub>4</sub> and read at 450nm. Ten sera obtained from volunteers prior to the COVID-19  
111 outbreak were used for comparison.

112 Total concentrations of Ig A, G and M were determined using commercially available  
113 reagents on the Alinity platform (Abbott Laboratories).

#### 114 **Flow cytometry**

115 Blood was collected in EDTA Vacutainer tubes and was analyzed using Multitest 6-Color  
116 TBNK reagent (337166) or anti-CD45-PerCP (345809)/anti-CD14-APC (345787) in  
117 Trucount tubes (340334) according to normal procedures using FACSCanto II flow  
118 cytometers (all from BD Biosciences, San Jose, CA).

#### 119 **SARS-CoV-2 Neutralizing antibody assay**

120 Neutralizing antibodies (NAb) were determined after inactivation of the complement  
121 in serum for 30 minutes at 56°C, by incubating 25 $\mu$ L of 2-fold dilutions (1/2 - 1/264) of each  
122 serum in maintenance medium (MM) with 25  $\mu$ L of 100TCID<sub>50</sub> of SARS-CoV-2 in duplicate

123 for two hours at 37°C. Thereafter the serum/virus mixture was added to confluent Vero cells  
124 in 96 well microtiter plates with 175 µL MM and incubated at 37°C in a CO<sub>2</sub> incubator. Ten-  
125 fold serial dilutions of the virus, 10-1,000 TCID<sub>50</sub>, were added in duplicate. The plates were  
126 examined daily, using an inverted microscope, and complete cytopathic effect (CPE) was  
127 usually complete in the virus only control-wells after three days. CPE was then recorded in  
128 the wells and the titer of the sera was calculated as previously described (14). Sera with  
129 antibody titers  $\geq 4$  were considered neutralizing.

### 130 **Statistical analysis**

131 Time to event analysis with interval censoring was used to compare time to seroconversion  
132 between groups (15). Differences between groups were analyzed using Welch's t-test and  
133 longitudinal changes with paired t-test.  $P < 0.05$  was considered statistically significant.  
134 Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc) and R  
135 4.0.0.

136

## 137 **Results**

### 138 **SARS-CoV-2-specific serum-IgG antibodies in severe and mild COVID-19**

139 Forty-seven patients provided a total of 156 serum samples (mean 3.3 per patient, range 1-7),  
140 5-117 days PSO. Of the 47 patients, 15/47 (32%) had severe and 32/47 (68%) had mild  
141 COVID-19 (Table 1). The patients with severe symptoms were older (mean age 58) and all  
142 male, compared to patients with mild symptoms (mean age 45, 56% female).

143 All 15 patients with severe COVID-19 developed SARS-CoV-2-specific IgG  
144 antibodies in serum, with seroconversion observed after median 11 (range 7–20) days (Fig.  
145 1A). Of the patients with mild symptoms, 29/32 (91%) developed detectable IgG antibodies,  
146 with seroconversion observed after median 22 (range 14–79) days (Fig. 1B). When  
147 accounting for the varying sampling times by using interval censoring, time to seroconversion

148 was still significantly shorter in patients with severe symptoms than in those with mild  
149 symptoms ( $P=0.04$ ). Furthermore, we found significantly higher concentrations of IgG  
150 antibodies in patients with severe symptoms (mean 107 AU/ml) than in patients with mild  
151 symptoms (mean 65 AU/ml) within 35 days PSO (Fig 1C). Within both groups, antibody  
152 concentrations did not change significantly in patients  $>75$  days, hence the differences  
153 between the groups remained (though no longer significantly ( $P=0.235$ , Fig 1C) due to fewer  
154 patients analyzed at this time-point).

155       Among patients with mild symptoms, 3/32 (9.4%) did not develop detectable IgG  
156 antibodies as determined using the commercially available assays during the follow-up  
157 period, 91–105 days PSO.

158

### 159 **Analysis of patients without detectable IgG-responses**

160 We assessed the three patients without detectable IgG-responses further (Table 2, Fig 2).  
161 Lowest observed Ct values in the non-IgG patients were of a similar range as in the patients  
162 who seroconverted (15.9–24.9 vs. 11.9–37.2). Flow cytometric analyses of peripheral blood  
163 cells in two of the non-seroconverting patients available for additional testing (days 91 and  
164 105 PSO) revealed no overt signs of immunodeficiency (Table 3). Total concentrations of  
165 IgG, IgA and IgM isotypes in serum sampled at the same time-points were also within the  
166 normal adult range, indicating no antibody deficiencies (Table 2).

167

### 168 **Neutralizing and RBD-specific antibodies in patients without detectable** 169 **IgG-responses**

170 To further investigate the humoral immune response against SARS-CoV-2 in the three  
171 patients without detectable IgG, neutralizing antibodies, considered the golden standard of  
172 anti-viral serological testing, were analyzed in serum samples collected days 78-91 PSO. All

173 3 patients had detectable NAb activity (Table 2), indicating that these patients had mounted a  
174 functional humoral immune response against SARS-CoV-2. To ascertain if the neutralizing  
175 activity could be explained by low antibody levels against the RBD undetected by the  
176 commercial assays, an in-house ELISA was used (Table 2, Fig 3). Indeed, the two patients  
177 with highest levels of neutralization had measurable anti-RBD-IgG in the same samples  
178 whilst the patient with low neutralizing activity lacked detectable anti-RBD-IgG (Table 2).  
179 Compared to late serum samples (>75 days PSO, n=21) from patients with detectable anti-  
180 SARS-CoV-2-IgG with mild and severe disease, these three patients had lower levels of anti-  
181 RBD-IgG, IgA and IgM (Fig 3).

182

## 183 **Discussion**

184 In this study, we describe IgG antibody responses in 47 patients during and after severe and  
185 mild COVID-19. Patients with severe disease seroconverted earlier and had higher maximum  
186 concentrations of anti-viral IgG than those with mild disease. Whilst all of the patients with  
187 severe symptoms seroconverted, three (9%) of the 32 patients with mild disease failed to  
188 produce levels of IgG detectable with commercial assays, even more than 90 days PSO.  
189 However, NAbS against SARS-CoV-2 were detected in all of these three patients.

190 Our results confirm previous findings that clinical severity of disease is associated  
191 with higher SARS-CoV-2-specific serum-IgG antibodies (16–19). Studies comparing time to  
192 seroconversion between these groups are still lacking and we show that clinical severity is  
193 also associated with significantly earlier seroconversion. Due to the long follow-up period of  
194 this study, we were also able to observe that all seroconverted patients with both mild and  
195 severe symptoms still have detectable IgG levels after more than 75 days. A recently  
196 published study reported that 97% of 37 patients with mild COVID-19 had decreased levels  
197 of IgG 2-3 months POS (20). In contrast, our study shows that several patients with both mild



198 and severe symptoms had increased in IgG concentrations over time. Of note, all of the  
199 patients in the severe group in this study were male. In a study comparing serum-IgG  
200 responses between the sexes, no significant differences were found between women and men  
201 with severe COVID-19 (21), suggesting that the differences in proportions of males within the  
202 groups are unlikely to explain the concentration differences.

203 In this study, we found that almost 10% of patients with mild COVID-19 did not  
204 develop detectable anti-SARS-CoV-2 IgG in serum as evaluated by assays used in clinical  
205 practice. Previous studies have similarly failed to detect IgG antibodies in patients with mild  
206 disease (22,23), but due to short follow-up (less than 25–50 days) no conclusions regarding  
207 the proportion of patients who do not seroconvert have been made in the belief that antibody  
208 levels become detectable later in time. We show that despite 90 days or more PSO, not all  
209 patients develop detectable levels of IgG in these assays. However, using a virus  
210 neutralization assay, considered the golden standard of serology testing, all patients with  
211 undetectable IgG using commercial methods had NAbs. Furthermore, when using an in-house  
212 RBD ELISA, the two patients with highest levels of NAbs also had detectable anti-RBD-IgG.  
213 Several other studies have seen a correlation between the magnitudes of NAbs and IgG  
214 against viral S-protein epitopes (10,24). These results suggest that 100% of patients had in  
215 fact seroconverted, compared to 91% detected when using commercial methods.

216 While none of the patients with undetectable IgG using the commercial assays had  
217 anti-RBD-IgA, interestingly, the patients with detectable IgG also had detectable anti-RBD-  
218 IgA >75 days PSO, with no difference in levels between mild and severe cases. Other studies  
219 have found serum-IgA after mild COVID-19 to be transient and undetectable after only one  
220 month post recovery (16,25), again highlighting the sensitivity of our in-house RBD-ELISA.  
221 It is unsurprising that the validated SARS-CoV-2 antibody assays used in clinical practice  
222 miss a proportion of positive samples which other assays may detect. In these situations, the

223 balance between assay sensitivity and specificity must be weighted to reduce the risk of false  
224 positives. This study demonstrates the risk of false negatives, in which low serum antibody  
225 levels may be detected with more sensitive assays.

226 We acknowledge several limitations in this study. The number and timing of serum  
227 sampling differed between patients; detectable IgG may have occurred before sampling,  
228 meaning that the exact timing of seroconversion is uncertain. Also, a larger proportion of  
229 patients in the mild group than the severe group have been available for late follow-up  
230 sampling.

231

## 232 **Conclusions**

233 We show that patients with severe COVID-19 both seroconvert earlier and develop higher  
234 concentrations of SARS-CoV-2-specific IgG than patients with mild symptoms. That not all  
235 COVID-19 patients develop detectable levels of IgG using two validated commercial  
236 methods, even over time, are vital for the interpretation of COVID-19 seroprevalence surveys  
237 and estimating the true prevalence in populations.

238

## 239 **Acknowledgements**

240 We thank Florian Krammer (Mount Sinai, NY, USA) and Adam Wheatley (University of  
241 Melbourne, Australia) for the RBD expression plasmids and the Mammalian Protein core  
242 facility (MPE) at the University of Gothenburg for protein production.

243

## 244 **References**

- 245 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus  
246 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases

- 247 from the Chinese Center for Disease Control and Prevention. Vol. 323, JAMA. 2020.  
248 p. 1239–42.
- 249 2. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia  
250 outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020.
- 251 3. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-  
252 Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.  
253 *Immunity*. 2020.
- 254 4. Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. Two-Year Prospective  
255 Study of the Humoral Immune Response of Patients with Severe Acute Respiratory  
256 Syndrome. *J Infect Dis*. 2006;193(6):792–5.
- 257 5. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, Malic LS, et al.  
258 Antibody Response and Disease Severity in Healthcare Worker MERS Survivors.  
259 *Emerg Infect Dis*. 2016;22(6):1113.
- 260 6. Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal Change of Severe Acute Respiratory  
261 Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019. *J*  
262 *Infect Dis*. 2020.
- 263 7. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses  
264 to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020;62:1–4.
- 265 8. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral  
266 Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*. 2020.
- 267 9. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.  
268 Virological assessment of hospitalized patients with COVID-2019. *Nature*.  
269 2020;581(7809):465–9.
- 270 10. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal  
271 profiles of viral load in posterior oropharyngeal saliva samples and serum antibody

- 272 responses during infection by SARS-CoV-2: an observational cohort study. *Lancet*  
273 *Infect Dis.* 2020;20(5):565–74.
- 274 11. WHO Working Group on the Clinical Characterisation and Management of COVID-19  
275 infection. A minimal common outcome measure set for COVID-19 clinical research.  
276 *Lancet Infect Dis.* 2020 Jun 12;0(0).
- 277 12. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection  
278 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance.* 2020  
279 Jan 23;25(3).
- 280 13. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahan M, et  
281 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med.*  
282 2020;5:1–4.
- 283 14. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche.  
284 *Naunyn Schmiedebergs Arch Exp Pathol Pharmacol.* 1931 Jul;162(4):480–3.
- 285 15. Fay MP, Shaw PA. Exact and asymptotic weighted logrank tests for interval censored  
286 data: The interval R package. *J Stat Softw.* 2010;36(2):1–34.
- 287 16. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al.  
288 Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus  
289 severe COVID-19. *bioRxiv.* 2020;5(4):2020.05.21.108308.
- 290 17. Yu H, Sun B, Fang Z, Zhao J, Liu X, Li Y, et al. Distinct features of SARS-CoV-2-  
291 specific IgA response in COVID-19 patients. *Eur Respir J.* 2020;4:2001526.
- 292 18. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG  
293 responses in COVID-19. *Cell & Mol Immunol.* 2020;9(7809):1–3.
- 294 19. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-  
295 CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis.* 2020.
- 296 20. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and

- 297 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med.*  
298 2020;1–5.
- 299 21. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2  
300 IgG antibody between male and female COVID-19 patients: A possible reason  
301 underlying different outcome between sex. *J Med Virol.* 2020 May 22;jmv.25989.
- 302 22. Lou B, Li T-D, Zheng S-F, Su Y-Y, Li Z-Y, Liu W, et al. Serology characteristics of  
303 SARS-CoV-2 infection since exposure and post symptom onset. *Eur Respir J.*  
304 2020;382:2000763.
- 305 23. Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al.  
306 Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections.  
307 *medRxiv.* 2020;2020.06.07.20124636.
- 308 24. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing Antibody  
309 Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their  
310 Implications. *SSRN Electron J.* 2020.
- 311 25. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the  
312 early neutralizing antibody response to SARS-CoV-2. *medRxiv.* 2020 Jun  
313 11;2020.06.10.20126532.

314

315

316

317

318

319

320

321

## 322 **Figure legends**

### 323 **Figure 1. SARS-CoV-2-specific serum IgG antibody responses in patients with severe** 324 **and mild COVID-19.**

325 Concentrations of serum IgG (AU/ml) over time in patients with severe (A, red) and mild (B,  
326 blue) disease. (C) Maximum concentrations of serum IgG (AU/ml) in early (1-35 days) and  
327 late (>75 days) follow-up. Cut-off for positive sample indicated by dotted line.

328

### 329 **Figure 2. SARS-CoV-2 viral load, IgG antibody concentration and symptom duration in** 330 **three IgG-negative patients >90 days post onset of symptoms.**

331 Ct values over time (blue circles, left y-axis), concentration of SARS-CoV-2-specific serum  
332 IgG antibodies over time (red triangles, right y-axis) and number of days of with symptoms  
333 (green bar, x-axis). Cut-off for positive viral sample indicated by dotted line.

334

### 335 **Figure 3. Antibody responses against the receptor-binding domain of SARS-CoV-2**

336 RBD-specific serum IgG (A), IgA (B) and IgM (C) antibodies in patients with severe  
337 symptoms (red, n=7), mild symptoms and IgG-positive (blue, n=14), mild symptoms and IgG-  
338 negative (green, n=3) collected 78-91 days post symptom onset. NC= negative controls (black  
339 dots, n=10).

340 **Table 1**

341

342 Demographic and clinical characteristics of 47 patients with COVID-19.

343

	Mild n=32	Severe n=15	Total n=47
<i>Characteristics</i>			
Age, mean (range)	45 (19-71)	58 (46-81)	49 (19-81)
Female, no. (%)	18 (56)	0 (0)	18 (38)
<i>Max level of care</i>			
Outpatient, no. (%)	32 (100) <sup>a</sup>	0 (0)	32 (68)
Hospitalized, no. (%)	0 (0)	15 (100)	15 (32)
ICU, no. (%)	0 (0)	12 (80)	12 (26)
<i>Comorbidities</i>			
Hypertension, no. (%)	1 (3)	5 (33)	4 (9)
Diabetes, no. (%)	0 (0)	2 (13)	2 (4)
Heart Disease, no. (%)	1 (3)	2 (13)	3 (6)
Cerebrovascular disease, no. (%)	0 (0)	1 (7)	1 (2)
Asthma, no. (%)	3 (9)	1 (7)	4 (9)

344 <sup>a</sup>7 patients in this group were isolated in hospital to prevent viral transmission according to  
 345 control policy at that time but did not require hospital care. ICU= Intensive Care Unit.

346

347 **Table 2**

348

349 Demographic, clinical and laboratory findings in three patients with undetectable levels of  
 350 serum IgG against SARS-CoV-2 after COVID-19 using commercially available kits.

351

352

	Patient 1	Patient 2	Patient 3
Age	46	19	43
Sex	Male	Female	Female
No. symptomatic days	28	29	20
Lowest Ct-value <sup>a</sup>	23	24.9	15.9
No. positive viral PCR	6	3	3
Total serum antibody concentrations <sup>b</sup>	<i>IgG</i> 8.1 <i>IgA</i> 1.8 <i>IgM</i> 0.48	<i>IgG</i> 10 <i>IgA</i> 1.2 <i>IgM</i> 1.4	<i>IgG</i> 9.7 <i>IgA</i> 0.9 <i>IgM</i> 1.5
$\alpha$ -SARS-CoV-2 IgG	Neg	Neg	Neg
Neutralizing ab titer <sup>c</sup>	12	8	48
$\alpha$ -RBD antibodies	<i>IgG</i> Pos <i>IgA</i> Neg <i>IgM</i> Neg	<i>IgG</i> Neg <i>IgA</i> Neg <i>IgM</i> Neg	<i>IgG</i> Pos <i>IgA</i> Neg <i>IgM</i> Neg

353 Blood samples analyzed for specific antibodies and total serum antibodies collected at day 76  
 354 (patient 2) and 91 (patient 1 and 3) post symptom onset. <sup>a</sup>Ct values <38 are considered  
 355 positive. <sup>b</sup>Titers >4 are considered positive. <sup>c</sup>Normal range: IgM 0.27-2.1, IgG 6.7-15, IgA  
 356 0.88-4.5 g/L. RBD=Receptor binding domain.

357

358

359 **Table 3**

360

361 Flow cytometric analysis of peripheral blood cells in two patients with undetectable levels of  
362 serum IgG against SARS-CoV-2 using commercially available kits after COVID-19.

363

Cell type	Phenotype	Patient 1 <sup>a</sup>	Patient 3	Normal range
T cells	CD3+	1,1	2	0,7 - 2,1
T helper cells	CD3+4+	0,69	1,19	0,3 - 1,4
T cytotoxic cells	CD3+8+	0,35	0,66	0,2 - 0,9
B cells	CD19	0,08	0,25	0,1 - 0,5
NK cells	CD3-56+	0,12	0,15	0,09 - 0,6
Classical monocytes	CD14+16-	0,17	0,31	0,26 – 0,38

364 <sup>a</sup>Samples collected at 105 (patient 1) and day 91 (patient 3) post symptom onset.


365

366




Fig. 1

A.



B.



C.






Fig 2

A. Patient 1



B. Patient 2



C. Patient 3




Fig. 3

